Beijing Tiantan Biological Products Co., Ltd.
600161
Classement en actions
#4320
Beijing Tiantan Biological Products Co., Ltd., established in 1998 and... Beijing Tiantan Biological Products Co., Ltd., established in 1998 and headquartered in Beijing, China, is actively involved in the full spectrum of blood product operations within China. This includes pioneering research and development, manufacturing, sales, and providing consultancy services. Its comprehensive product line features critical blood-derived medicines such as intravenous immunoglobulin, human albumin, and various specialized human immunoglobulins for conditions like hepatitis B (both standard and freeze-dried formulations) and tetanus, alongside other general human immunoglobulin preparations and intravenous blood system solutions. The company operates as a subsidiary of China National Biotec Group Company Limited.
Prix de l'action
$1.81
Capitalisation boursière
$3.59B
Changement (1 jour)
-0.90%
Changement (1 an)
-32.39%
Pays
CN
Échange Beijing Tiantan Biological Products Co., Ltd. (600161)
Catégorie
Healthcare
Revenus pour Beijing Tiantan Biological Products Co., Ltd. (600161)
Revenus en Oct 2026 TTM : 0
Selon les derniers rapports financiers de Beijing Tiantan Biological Products Co., Ltd., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Beijing Tiantan Biological Products Co., Ltd. de 2001 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2025 | $877.40M | 6.17% |
| 2024 | $826.38M | 12.92% |
| 2023 | $731.85M | 18.47% |
| 2022 | $617.77M | -4.52% |
| 2021 | $646.98M | 22.66% |
| 2020 | $527.44M | 11.91% |
| 2019 | $471.31M | 10.61% |
| 2018 | $426.11M | 11.64% |
| 2017 | $381.67M | 23.92% |
| 2016 | $308.00M | 23.62% |
| 2015 | $249.16M | -15.51% |
| 2014 | $294.89M | -2.60% |
| 2013 | $302.76M | 25.67% |
| 2012 | $240.92M | 8.92% |
| 2011 | $221.19M | 21.43% |
| 2010 | $182.15M | 13.03% |
| 2009 | $161.16M | 61.08% |
| 2008 | $100.05M | 37.71% |
| 2007 | $72.66M | 37.07% |
| 2006 | $53.01M | 24.61% |
| 2005 | $42.54M | 21.37% |
| 2004 | $35.05M | 18.43% |
| 2003 | $29.59M | 22.68% |
| 2002 | $24.12M | 28.78% |
| 2001 | $18.73M | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
